ASCO GU 2018: Real-World Experience with Docetaxel for Castration-Sensitive Prostate Cancer from a Population-Based Analysis
San Francisco, CA (UroToday.com) Phase III clinical trials have demonstrated efficacy with an overall survival (OS) benefit for the addition of docetaxel (DOC) to androgen deprivation therapy (ADT) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC). The clinical effectiveness of DOC with ADT in the general patient population remains undefined.
ASCO GU 2018: Evaluation of a 29 Gene Classifier for Basal/Non Basal Prediction in Muscle-Invasive Bladder Cancer FFPE Samples
San Francisco, CA (UroToday.com) Recent and independent muscle-invasive bladder cancer (MIBC) molecular classifications identified the basal / squamous-like (BASQ) tumors as an intrinsic and robust subtype, harboring a poor outcome and a possible chemo-sensitivity to cisplatin based regimen. The authors presented a study aimed to evaluate the diagnostic accuracy of a Nanostring classifier for tumor subtype prediction on fresh frozen plasma embeded (FFPE) specimens.
ASCO GU 2018: Assessing The Quality-adjusted Time Without Symptoms of Disease Progression or Toxicity (Q-TWiST) In Immuno-Oncology: An Application to Nivolumab vs. Everolimus in Previously Treated Advanced RCC
San Francisco, CA (UroToday.com) At this morning’s GU ASCO kidney cancer poster session, Ruchit Shah and colleagues presented results from the assessment of quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) among patients treated with nivolumab or everolimus in advanced RCC patients.
ASCO GU 2018: Adrenal Cortical Carcinoma: Finding the Wolf in Sheep’s Clothing
San Francisco, CA (UroToday.com) Dr. Mayo-Smith from Boston’s Brigham and Women’s Hospital provided the Keynote Lecture for Adrenal Cortical Carcinoma (ACC). Dr. Mayo-Smith started by highlighting that when looking at the NCI website for ACC, it states several telling points: (i) NCI does not have evidence-based information about prevention of ACC, (ii) rare endocrine cancers have novel genetic alterations, and (iii) NCI does not have evidence-based information about screening for ACC.
ASCO GU 2018: Thromboembolic Complications in Germ Cell Tumor Patients: Should Use of Peripherally Inserted Central Catheters be Pursued?
San Francisco, CA (UroToday.com) Dr. Louis Francois and his colleagues from France presented the results of thromboembolic complications among patients with germ cell tumors. Patients with germ cell tumors receiving cisplatin-based chemotherapy are at high risk of thromboembolic events. The objective of this study was to assess predictors of thromboembolic events in single institution setting.
ASCO GU 2018: Effect of Number of CT Scans During Follow-Up of Patients with Clinical Stage I Seminoma: A Trial-Level Meta-Analysis
San Francisco, CA (UroToday.com) Dr. Patrizia Giannatempo presented results of her team’s trial level-analysis assessing the effect of number of CT scans during follow-up of patients with clinical stage I (CSI) seminoma. Despite the overall high cure-rate for patients with CSI seminoma regardless of the intervention used, huge discrepancy exists in the number of CT scans that are proposed to patients during the follow-up period, mainly during active surveillance. The objective of this study was to assess the impact of such a discrepancy in diagnosing patients with a high-risk relapse using published literature and a meta-analysis.
ASCO GU 2018: Is Surveillance without Immediate Treatment an Option for Newly Diagnosed Testicular Germ-cell Cancer Patients with Borderline Size Retroperitoneal Lymph Nodes on CT Scan?
San Francisco, CA (UroToday.com) Dr. Nadav Milk and colleagues from Israel presented results of surveillance for patients with borderline size retroperitoneal nodes on CT scan. The AJCC TNM staging system for testicular cancer does not set a minimal diameter to define positive lymph nodes on CT scan. However, it is common to refer to lymph nodes ≥ 1 cm in diameter as positive, even though benign lymph nodes in the borderline size of 1-1.5cm are common. The objective of this study was to describe the outcome of testicular cancer patients with borderline size retroperitoneal lymph nodes of undetermined significance managed initially with surveillance.